TCL Archive High Dose Chemotherapy Significantly Prolongs Survival In ECOG Clinical Trial November 28, 2008
TCL Archive FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says. January 14, 2005
TCL Archive Senate Subcommittee Votes $970 Million for NCI In FY 1980; Magnuson Cancer Support Holds Firm June 23, 1978
